---
title: "What Is SMA? Kerala’s Medicine Controversy — What Are the Facts?"
english_title: "Kerala SMA Medicine Row Explained: Facts, Controversy and Government Response"
publisher: "Truevision English News"
canonical_url: "https://english.truevisionnews.com/news/388262/kerala-sma-medicine-row-explained"
published_at: "2026-10-23T06:38:00+05:30"
category: "Big Story"
language: "en"
image: "https://cf.zdn.im/img/truevisionnews.com/0/image-uploads/6adab4bf15747_kerala-sma-medicine-row-explained.jpg"
keywords: ["SMATreatment", "KeralaHealth", "Risdiplam", "NatcoPharma", "RareDiseaseCare"]
---

# What Is SMA? Kerala’s Medicine Controversy — What Are the Facts?

> **Lead Summary:** **Thiruvananthapuram: **Kerala’s treatment model for an extremely rare genetic disease has become the subject of a major controversy. The issue arose after children with spinal muscular atrophy , who had been receiving medicines purchased by the state government at considerable expense and distributed free, were instead given bottles supplied by the manufacturer as free samples for doctors. A label on these bottles triggered the controversy.

## Article Content

**Thiruvananthapuram: **Kerala’s treatment model for an extremely rare genetic disease has become the subject of a major controversy. The issue arose after children with spinal muscular atrophy , who had been receiving medicines purchased by the state government at considerable expense and distributed free, were instead given bottles supplied by the manufacturer as free samples for doctors. A label on these bottles triggered the controversy.

What Is SMA?

Spinal muscular atrophy is a serious genetic disorder affecting motor nerve cells in the spinal cord. It is associated with the absence of the SMN1 gene, which is essential for normal motor function.

As a result, muscles progressively weaken, potentially leaving children unable to sit, stand, walk or even breathe. Type 1 is the most severe form described here. If both parents carry the gene associated with the condition, their child has a 25% chance of developing the disease.

1. Risdiplam: An oral medicine taken daily.

2. Spinraza: An injection administered into the spinal canal.

3. Zolgensma: A one-time gene therapy. It is among the world’s most expensive medicines, costing approximately ₹16 crore to ₹18 crore in India. The report states that it can be administered only to children under two.

Kerala was the first state in the country to introduce a comprehensive government programme for SMA treatment, according to the report. The initiative is called KARE — Keralam United Against Rare Diseases.

Through the programme, the government had been providing Evrysdi, the risdiplam medicine manufactured by Switzerland-based Roche, free to 118 children under 12. The government paid ₹1.5 lakh per bottle, while the market price exceeded ₹6 lakh.

The issue began when the government decided to replace Roche’s medicine with Natsmart, a generic medicine manufactured by Hyderabad-based Natco Pharma.The price difference is substantial: Roche’s medicine costs ₹6 lakh, while Natco’s medicine has a maximum retail price of ₹15,900. According to the report, the government obtains it through a tender at approximately ₹8,500 per bottle, with one bottle supplied free for every three purchased. The report describes this as a 97% price reduction.

> Parents became alarmed after finding “Physician Sample / For Clinical Trials Only” printed on five bottles recently supplied by Thiruvananthapuram’s SAT Hospital.

> “Are our children being subjected to experiments?” they asked.The issue subsequently became a political controversy. Pinarayi Vijayan, described in the report as the opposition leader, and former health ministers P.K. Sreemathi, K.K. Shailaja and Veena George raised serious allegations.

What Do the Government and the Company Say?

1. They say the medicine received approval from the Central Drugs Standard Control Organisation (CDSCO) on April 7, 2025. They also maintain that the Delhi High Court and the Supreme Court ruled in Natco’s favour in the patent dispute.

> 2. They attribute the “Clinical Trial” label either to a printing error or to labels from a sample batch supplied to doctors during the earlier patent dispute with Roche. They maintain that there is no difference in the medicine. SAT Hospital authorities say sample stock was supplied temporarily because delivery of the ordered medicine was delayed.

3. Health Minister K. Muraleedharan said the decision to change the medicine was taken during the previous Left Democratic Front government’s tenure, following an expert committee’s recommendation. The objective, he said, was to make the medicine available to more children.

> Following the concerns, the Health Department has decided to take back medicines carrying the “sample” label and supply a new batch.

Many of the children had shown improvements in their health after taking Roche’s medicine for years. Their main concern is whether a sudden change in medicine could affect treatment outcomes.

Organisations including Cure SMA Foundation of India have called for the complete disclosure of studies on the generic medicine’s bioequivalence. They have also sought counselling before children are switched to the replacement medicine.

Experts cited in the report say the active molecule, risdiplam, remains the same and that only the brand has changed. Public health expert Dr B. Ekbal is among those supporting the switch to the generic medicine.

The government argues that the lower price would allow approximately 400 children, instead of 118, to receive medicine within a budget of ₹30 crore.

> However, questions remain: Did supplying bottles marked “Physician Sample” through a free distribution programme violate the Drugs and Cosmetics Rules? Did the government fail to secure parents’ trust before making the change?

### Related Links & Sources
- [Original Story Source](https://english.truevisionnews.com/news/388262/kerala-sma-medicine-row-explained)